Boston Scientific (STU:BSX) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BSX Boston Scientific Corp STU:BSX
80 GF Score
Price €37.85
GF Value €92.19
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Boston Scientific Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Boston Scientific  (STU:BSX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Boston Scientific Cyclically Adjusted PS Ratio Related Terms


Boston Scientific Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Cyclically Adjusted PS Ratio Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.21 6.30 6.93 10.99 9.25

Boston Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.56 9.48 9.20 5.87 3.97

STU:BSX vs EW, DXCM, GEHC: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Boston Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cyclically Adjusted PS Ratio falls into.


STU:BSX
80GF Score
Boston Scientific Corp STU:BSX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Boston Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Boston Scientific's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.174/333.9520*333.9520
=3.174

Current CPI (Jun. 2026) = 333.9520.

Boston Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.367 241.428 1.891
201612 1.471 241.432 2.035
201703 1.458 243.801 1.997
201706 1.474 244.955 2.010
201709 1.358 246.819 1.837
201712 1.489 246.524 2.017
201803 1.386 249.554 1.855
201806 1.494 251.989 1.980
201809 1.465 252.439 1.938
201812 1.596 251.233 2.121
201903 1.559 254.202 2.048
201906 1.662 256.143 2.167
201909 1.724 256.759 2.242
201912 1.857 256.974 2.413
202003 1.633 258.115 2.113
202006 1.289 257.797 1.670
202009 1.591 260.280 2.041
202012 1.577 260.474 2.022
202103 1.597 264.877 2.013
202106 1.783 271.696 2.192
202109 1.733 274.310 2.110
202112 1.905 278.802 2.282
202203 1.875 287.504 2.178
202206 2.117 296.311 2.386
202209 2.185 296.808 2.458
202212 2.205 296.797 2.481
202303 2.184 301.836 2.416
202306 2.271 305.109 2.486
202309 2.198 307.789 2.385
202312 2.346 306.746 2.554
202403 2.398 312.332 2.564
202406 2.578 314.175 2.740
202409 2.576 315.301 2.728
202412 2.869 315.605 3.036
202503 2.967 319.799 3.098
202506 2.990 322.561 3.096
202509 2.898 324.800 2.980
202512 3.036 324.054 3.129
202603 2.975 330.213 3.009
202606 3.174 333.952 3.174

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Boston Scientific (STU:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of €37.85 is trading 58.9% below its estimated GF Value™ of €92.19. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for STU:BSX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €92.19 vs. price of €37.85 (58.9% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the STU:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
80GF Score

Get the complete analysis for STU:BSX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.85
Price
€92.19
GF Value